PROTAC has emerged as a new modality with the potential to revolutionize drug discovery strategy providing significant opportunity to transform the way medicinal chemistry and discovery programs are planned and executed. Aragen has expertise in working with degrader technologies such as PROTAC and Molecular Glue. Our continuum offering of chemistry, assay development & screening, DMPK, formulation development, in vivo efficacy, and exploratory toxicology will help accelerate TPD programs from Hit identification until IND filing. Aragen offers the expertise and experience as a drug discovery partner to enable organizations to successfully execute and drive TPD-based programs.